Lapatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='450' side='right' scene='Lapatinib/Lapatinib/2' caption='Lapatinib, also known as Tykerb ([[3bbt]])'> | ||
__TOC__ | |||
===Better Known as: Tykerb=== | ===Better Known as: Tykerb=== | ||
* Marketed By: GlaxoSmithKline | * Marketed By: GlaxoSmithKline | ||
| Line 6: | Line 7: | ||
* Date of FDA Approval (Expiration): 2007 (2017) | * Date of FDA Approval (Expiration): 2007 (2017) | ||
* 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref> | * 2009 Sales (Projected Peak): $150 Million ($4.5 Billion)<ref>http://money.cnn.com/2006/06/03/news/companies/glaxo_breastcancer/index.htm</ref> | ||
* Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast cancer. | * Importance: It is one of the newest treatments for cancer. Complaints over the high cost ($22,000) for a treatment course which only prolongs survival in breast cancer patients by less than 2 months. It is particularly effective against HER2-positive breast [[cancer]]. | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
| Line 22: | Line 23: | ||
</tr> | </tr> | ||
</table> | </table> | ||
</StructureSection> | |||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
